# A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

> **NCT03743246** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 21 (actual)

## Conditions studied

- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** JCAR017
- **DRUG:** Lymphodepleting
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03743246
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-17
- **Primary completion:** 2024-01-26
- **Final completion:** 2024-01-26
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Absence of significant therapeutic benefit over existing therapies
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03743246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03743246, "A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03743246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*